Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Clinical trial investigating the chemotherapeutic compound treosulfan (Trecondi® Ideogen) in myeloma patients.
Trial Details
- NCT ID
- NCT05636787
- Phase
- PHASE2
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Status
- RECRUITING
- Cancer Type
- Multiple Myeloma
- Interventions
- Locations (sample)
- Bern, Switzerland|46.94809,7.44744
Key Eligibility Criteria
- Eligible are myeloma patients after standard first-line induction treatment. Additional induction regimens in refractory myeloma patients are allowed.
- Patients must be considered fit for subsequent consolidation with high-dose chemotherapy with autologous stem cell transplantation.
- Patients must be aged 18-75 years.
- Patients must have an ECOG \<3.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Multiple Myeloma Trials on Trialify →